Open access
Open access
Powered by Google Translator Translator

General Gynecology

Review: Primary care-based cardiovascular disease risk management after adverse pregnancy outcomes.

1 Feb, 2022 | 08:29h | UTC

Primary Care–Based Cardiovascular Disease Risk Management After Adverse Pregnancy Outcomes: a Narrative Review – Journal of General Internal Medicine (if the link is paywalled, try this one)

Commentary: Better management of long-term heart disease risk needed following complicated pregnancies – Boston Medical Center

See also: thread from the author on Twitter summarizing the article

Related:

A national cohort study in Sweden showed pregnancy complications (preeclampsia or eclampsia, gestational hypertension, gestational diabetes, preterm birth, small for gestational age, and stillbirth) are associated with increased risk of cardiovascular disease later in life.

AHA Scientific Statement | Adverse Pregnancy Outcomes and Cardiovascular Disease Risk

Consensus statement: Cardiovascular health after menopause transition, pregnancy disorders, and other gynecologic conditions

Cohort Study: Preeclampsia and Cardiovascular Disease

Cohort Study: Cardiovascular Disease After Hypertensive Disorders of Pregnancy Largely Explained by Conventional Cardiovascular Risk Factors (recent studies on the subject)

 

M-A: The diagnostic accuracy of syndromic management for genital ulcer disease.

1 Feb, 2022 | 08:12h | UTC

The Diagnostic Accuracy of Syndromic Management for Genital Ulcer Disease: A Systematic Review and Meta-Analysis – Frontiers in Medicine

 

Perspective: From vaginal laser treatment to spa breaks – it’s the great menopause gold rush.

27 Jan, 2022 | 09:36h | UTC

From vaginal laser treatment to spa breaks – it’s the great menopause gold rush – The Guardian

 

RCT: Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone for the treatment of gonorrhea.

25 Jan, 2022 | 09:20h | UTC

Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial – The Lancet Infectious Diseases (link to abstract – $ for full-text)

 

Commentary on Twitter (thread – click for more)

 

RCT: Lactic acid gel vs. metronidazole for recurrent bacterial vaginosis in women aged 16 years and over.

24 Jan, 2022 | 08:13h | UTC

Lactic acid gel versus metronidazole for recurrent bacterial vaginosis in women aged 16 years and over: the VITA RCT – Health Technology Assessment

 

Practical Guide: Management of bladder pain syndrome.

24 Jan, 2022 | 07:52h | UTC

Management of Bladder Pain Syndrome (BPS): A Practical Guide – Advances in Urology

 

O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee.

20 Jan, 2022 | 08:59h | UTC

O-RADS MRI Risk Stratification System: Guide for Assessing Adnexal Lesions from the ACR O-RADS Committee – Radiology

 

Review: Diagnosis and treatment of polycystic ovary syndrome.

20 Jan, 2022 | 08:54h | UTC

Diagnosis and Treatment of Polycystic Ovary Syndrome – JAMA (free for a limited period)

 

Cohort Study: Factors associated with 10-year declines in physical health and function among women during midlife.

19 Jan, 2022 | 08:29h | UTC

Factors Associated With 10-Year Declines in Physical Health and Function Among Women During Midlife – JAMA Network Open

Commentary: Four Factors in Midlife Predict a Healthy Old Age for Women – HealthDay

 

Association of hormonal contraceptive use with adverse health outcomes: an umbrella review of meta-analyses of randomized clinical trials and cohort studies.

18 Jan, 2022 | 09:29h | UTC

Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies – JAMA Network Open

 

M-A: Combined oral contraceptives may improve overall premenstrual symptomatology but are not helpful for premenstrual depressive symptoms.

14 Jan, 2022 | 07:49h | UTC

Efficacy of combined oral contraceptives for depressive symptoms and overall symptomatology in premenstrual syndrome: pairwise and network meta-analysis of randomized trials – American Journal of Obstetrics & Gynecology

Commentary: ‘Optimal’ treatment for premenstrual depressive symptoms remains elusive – Healio (free registration required)

 

Risk of reoperation 10 years after surgical treatment for stress urinary incontinence: a national population-based cohort study.

14 Jan, 2022 | 07:51h | UTC

Risk of reoperation 10 years after surgical treatment for stress urinary incontinence: a national population-based cohort study – American Journal of Obstetrics & Gynecology

 

Commentary on Twitter

 

Review: Diagnosis and treatment of sexually transmitted infections.

13 Jan, 2022 | 08:38h | UTC

Diagnosis and Treatment of Sexually Transmitted Infections: A Review – JAMA (free for a limited period)

 

Systematic Review: The effectiveness and safety of treatments for recurrent vulvovaginal candidiasis.

11 Jan, 2022 | 02:24h | UTC

Treatment for recurrent vulvovaginal candidiasis (thrush) – Cochrane Library

Summary: The effectiveness and safety of treatments for recurrent vulvovaginal candidiasis (thrush) – Cochrane Library

 

FDA approves first injectable treatment for HIV pre-exposure prevention.

8 Jan, 2022 | 23:04h | UTC

FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention – U.S. Food & Drug Administration

Commentaries:

NIH celebrates FDA approval of long-acting injectable drug for HIV prevention – NIH News Releases

A new injection to prevent HIV, rather than pills, is a game-changer, scientists say – NPR

Related:

CDC Guidance: Preexposure Prophylaxis for Prevention of HIV Acquisition Among Adolescents

Study Shows High Burden of STI Among Individuals Using Preexposure Prophylaxis for the Prevention of HIV Infection

USPSTF Statement: Preexposure Prophylaxis for the Prevention of HIV Infection

British Guidelines on the Use of HIV Pre–exposure Prophylaxis (PrEP) (several guidelines on the subject)

New Protocol for HIV Prevention Drug Reduces The Number Of Pills Required

 

Abortion safety and use with normally prescribed Mifepristone in Canada.

16 Dec, 2021 | 08:51h | UTC

Abortion Safety and Use with Normally Prescribed Mifepristone in Canada – New England Journal of Medicine

News Release: Prescribing the abortion pill without restrictions is safe and effective, study finds – University of British Columbia

 

Short Review: Lymphogranuloma venereum.

14 Dec, 2021 | 08:42h | UTC

Lymphogranuloma venereum – Canadian Medical Association Journal

 

NICE Guideline | Pelvic floor dysfunction: prevention and non-surgical management.

13 Dec, 2021 | 09:43h | UTC

Pelvic floor dysfunction: prevention and non-surgical management – National Institute for Health and Care Excellence

 

Review: Endometrial cancer.

13 Dec, 2021 | 08:43h | UTC

Endometrial cancer – Nature Reviews Disease Primers (free for a limited period – if the link is paywalled, try this one)

Infographic: Endometrial cancer (free for a limited period – if the link is paywalled, try this one)

 

Cohort Study: Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality.

13 Dec, 2021 | 08:42h | UTC

Association of bilateral salpingo-oophorectomy with all cause and cause specific mortality: population based cohort study – The BMJ

Commentary: Bilateral salpingo-oophorectomy may have risks for younger women, but safe for post-menopausal patients – News Medical

 

Commentary on Twitter

 

Evaluation and management of pelvic organ prolapse.

8 Dec, 2021 | 09:50h | UTC

Evaluation and Management of Pelvic Organ Prolapse – Mayo Clinic Proceedings

 

RCT: Cytoreductive surgery for relapsed ovarian cancer.

2 Dec, 2021 | 09:51h | UTC

Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer – New England Journal of Medicine

 

[Not published yet] Single-dose HPV vaccine highly effective, researchers say – “Results of randomized controlled trial in Kenya bring new energy to eliminate cervical cancer worldwide”.

21 Nov, 2021 | 22:56h | UTC

Single-dose HPV vaccine highly effective, researchers say – University of Washington School of Medicine

Related:

A national HPV vaccination program in England was associated with an estimated reduction in cervical cancer rates of 87% for those offered the vaccine at age 12–13 years.

Three-year follow-up of 2-dose versus 3-dose HPV vaccine

Nationwide cohort study in Sweden shows HPV vaccination linked to reduced risk of invasive cervical cancer

CDC: 92% of Human Papillomavirus–Attributable Cancers can be Targeted by HPV Vaccination

Meta-Analysis: Population-level Impact of HPV Vaccination Programs

 

Recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic.

19 Nov, 2021 | 10:33h | UTC

British Gynaecological Cancer Society recommendations for women with gynecological cancer who received non-standard care during the COVID-19 pandemic – International Journal of Gynecological Cancer

 

Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.

10 Nov, 2021 | 06:57h | UTC

Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary: Choosing between antipsychotics to reduce the risk of breast cancer in women with schizophrenia – The Mental Elf

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.